Challenging the status quo: a framework for mechanistic and human-relevant cardiovascular safety screening
Traditional approaches to preclinical drug safety assessment have generally protected human patients from unintended adverse effects.However, these assessments typically occur too late to make changes in the formulation or in phase 1 and beyond, are highly dependent on animal studies and have the potential to lead to the termination of useful drugs